Humana Inc. (HUM) is deepening its commitment to value-based care with a new oncology partnership involving Evolent Health and the American Oncology Network (AON). The collaboration introduces a cancer care model aimed at improving treatment access, promoting evidence-based clinical decisions, and reducing administrative burdens for patients and providers. The model is now active across AON clinics in eight states, allowing participating oncology practices that meet quality and treatment standards to skip traditional prior authorization for most anticancer drug therapies. This could accelerate treatment initiation and ease administrative workloads for physicians.
The initiative also includes provider education, performance scorecards, and automated electronic health record (EHR) reminders to guide appropriate treatment decisions. The model leverages data analytics through Meaningful Insights Biotech Analytics (MiBA), which uses real-time EHR data to generate clinical insights and support personalized cancer care. By analyzing clinical patterns, the technology aims to enhance treatment planning, promote evidence-based practices, and improve care quality.
For Humana, this partnership extends its value-based care strategy into complex and costly specialty treatments. The collaboration builds on a 20-year relationship with Evolent, integrating payers, oncology providers, and technology to improve care coordination, promote evidence-based treatment decisions, and enhance the patient experience while managing healthcare spending more effectively.
Competitors like UnitedHealth Group Incorporated (UNH) and Elevance Health, Inc. (ELV) are also active in the value-based care space. UnitedHealth’s Optum offers oncology care management solutions, while Elevance Health’s Carelon operates an Oncology Medical Home model with risk-sharing arrangements and predictive analytics to improve care coordination.
Humana’s stock has surged 82.2% over the past year, outperforming the industry’s 25.6% rise. The company trades at a forward price-to-earnings ratio of 29.08, well above the industry average of 15.72. The Zacks Consensus Estimate for Humana’s 2026 earnings is $9.36 per share, reflecting a 45.4% drop from the previous year. HUM stock currently holds a Zacks Rank #1 (Strong Buy).